in

Novel treatment regimen appears well tolerated, beneficial to children with relapsed brain tumors

Novel treatment regimen appears well tolerated, beneficial to children with relapsed brain tumors

Theodore S. Johnson, MD/PhD. Credit: Michael Holahan

The first in-human-study of a new immunotherapy that blocks a natural enzyme tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.


Posted by Editor

Primark Owner Raises Outlook on Consumer Resilience

Primark Under Pressure From Inflation and Weak Sterling

Inside Meta's scramble to catch up on A.I.

Inside Meta’s scramble to catch up on A.I.